Drug Trial Radar · NCT03730662
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Last checked: Nov 20, 2026Latest source record: Feb 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,002
Actual
Start
Nov 20, 2018
Primary completion
Jan 22, 2021
Study completion Apr 22, 2021
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 5, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial is to assess the efficacy and safety of tirzepatide taken once a week to insulin glargine taken once daily in participants with type 2 diabetes and increased cardiovascular risk. The study will last about 108 weeks and may include up to 30 visits.
Conditions
- Type 2 Diabetes Mellitus
Interventions
TirzepatideDrug
Administered SC.
Insulin GlargineDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)Time frame: Baseline, Week 52
Locations
216 sites in 15 countries. Site status is shown where the registry gives one.
Advanced Research Center
Anaheim, California
Valley Clinical Trials, Inc.
Covina, California
Marin Endocrine Associates
Greenbrae, California
National Research Institute
Huntington Park, California
Scripps Whittier Diabetes Institute
La Jolla, California
First Valley Medical Group
Lancaster, California
National Research Institute
Los Angeles, California
Catalina Research Institute, LLC
Montclair, California
Monterey Endocrine & Diabetes Institute, Inc.
Monterey, California
Valley Clinical Trials, Inc.
Northridge, California
Desert Medical Group Inc
Palm Springs, California
Havana Research Institute
Pasadena, California
Western University of Health Sciences
Pomona, California
LCGK Research
San Carlos, California
Olive View Medical Center
Sylmar, California
University Clinical Investigators, Inc.
Tustin, California
Touro University
Vallejo, California
Coastal Metabolic Research Centre
Ventura, California
Diablo Clinical Research
Walnut Creek, California
Chase Medical Research, LLC
Waterbury, Connecticut
ALL Medical Research, LLC
Cooper City, Florida
Advanced Pharma Research
Cutler Bay, Florida
South Florida Wellness & Clinical Research Institute
Margate, Florida
Suncoast Research Group, LLC
Miami, Florida
New Horizon Research Center
Miami, Florida
Clinical Neuroscience Solutions Inc
Orlando, Florida
Progressive Medical Research
Port Orange, Florida
Primary Care Specialists, LLC
Atlanta, Georgia
Rocky Mountain Diabetes and Osteoporosis Center
Idaho Falls, Idaho
Solaris Clinical Research
Meridian, Idaho
Saltzer Medical Group. P.A.
Nampa, Idaho
Northwestern Feinberg School of Medicine
Chicago, Illinois
NorthShore University HealthSystem
Skokie, Illinois
University of Iowa Hospital & Clinic
Iowa City, Iowa
Iowa Diabetes Research
West Des Moines, Iowa
Cotton O'Neil Diabetes and Endocrinology Center
Topeka, Kansas
Robley Rex VAMC
Louisville, Kentucky
NECCR PrimaCare Research, LLC
Fall River, Massachusetts
AA Medical Research Center
Flint, Michigan
Troy Internal Medicine, PC
Troy, Michigan
Showing 40 of 216 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.